Renault, Elekta, Tietoevry and a number of others have recently reset expectations with investors.
Get this delivered to your inbox, and more info about our products and services.
A failed acquisition bid, U.S. pricing deals, and boardroom drama pose challenges for the Danish pharma giant.
The Wegovy obesity drug maker on Wednesday announced plans to trim 11.5% of its workforce.
Novo Nordisk CEO Mike Doustdar discusses the pharma giant's Q4 reporting, uptake of obesity drugs and how he plans to navigate…
Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its 2026…
Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for its…
Eli Lilly's stock is soaring while Novo Nordisk is sinking. Why it makes sense to stick with the market winner, despite its…
